Navigation Links
Specialty Blades, Inc. Expands Management Team With New VP Engineering
Date:9/14/2007

STAUNTON, Va., Sept. 14 /PRNewswire-USNewswire/ -- Michael Bond has been named the VP Engineering for IncisionTech/Specialty Blades. Bond joins the company following nearly 30 years in various roles for Gillette, including most recently as the Assistant Director of Blade Process Engineering. Bond has a wealth of experience in engineering management that will enable continued advancement of leading edge technologies for IncisionTech and Specialty Blades.

"The global markets we serve are expanding in both size and complexity, leading our business through a period of transformational growth. We are excited about the opportunity to have Mike as a key member of our management team," said Peter Harris, Specialty Blades' President and CEO. "Mike will lead our efforts to expand our Center of Excellence for incisional products and compete on a global basis by deploying innovative and advanced manufacturing technologies."

About Specialty Blades

Specialty Blades helps flexible packaging and other industrial companies improve their cutting, sealing and separating processes by providing the very best knives and blades for their application. No other potential partner has our unique set of skills or technologies that produces parts that improve the cutting process by improving blade wear, reducing scrap, and decreasing machine downtime. More information can be found on Specialty Blades at http://www.specialtyblades.com.

About IncisionTech

IncisionTech provides critical cutting and piercing components and sub- assemblies used in surgical devices. Its unique position in the surgical market comes from a 100% focus on cutting and piercing device functionality. This makes IncisionTech the strategic partner of choice for medical device OEMs seeking to improve patient outcomes through better device performance. For more information about IncisionTech visit

SOURCE Specialty Blades, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. All Specialty Care Treatments Will Be Offered At Belle Vue.
2. Inhospitable Response Curtail Growth Of Specialty Hospitals: United States
3. Apollo to Open Super-specialty Hospital in Oman by Year-end
4. Envisaged Specialty Training Programme For Junior Doctors Encounters a Speed Breaker
5. Reliance Group to Develop Specialty Blood Products
6. Vasan Group to Open Eight Specialty Eye Hospitals
7. Early Prostate Cancer: Specialty of Physician Influences Type of Therapy Received
8. The Cleveland Clinic Expands Its Services across the World via the Net
9. Ranbaxy Expands By Acquiring A Generic Company In Belgium
10. Insulin and Growth Hormone, Expands Life Span?
11. Health Insurance Company Expands Product Range
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...nts were checked, only 39% met treatment goals , ...dangers of high blood pressure are well-known, but...e screening in doctor,s offices and a low percenta... blood pressure goals after diagnosis. , The St...hed in the May issue of Hypertension, found that...
(Date:5/12/2008)...May 12, 08:30 a.m. EDT at ...ay 12 /PRNewswire-FirstCall/ -- Isis,Pharmaceutica...ncial results,for the quarter ended March 31, 2008...a net operating loss (NOL) of $5.1 million, exclud... compared to a pro forma NOL,of $18.5 million in t...
(Date:5/12/2008)...all/ - Innolife Pharma, Inc.,(Other OTC:INNP.PK - ...ht,months regarding the formation of a joint ventu...negotiations where final written terms have been,s... Company,s very first,product acquisition. It shou... over this extended period due to the successful, ...
(Date:5/12/2008)...s of over $25 million, OWINGS MILLS, Md., May 12 ...ED ) announced today first quarter financial resul...ial highlights included:, -- First quarter revenu...75.8% vs. 74.8%, -- The direct sales segment of T...of 63% year-over-year;, -- Medifast Weight Contro...
Breaking Medicine News(10 mins):Health News:High Blood Pressure Still Slipping Past Doctors 2Health News:High Blood Pressure Still Slipping Past Doctors 3Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 2Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 3Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 4Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 5Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 6Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 7Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 8Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 9Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 10Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 11Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 12Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 13Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 14Health News:Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture 2Health News:Medifast Announces First Quarter 2008 Financial Results 2Health News:Medifast Announces First Quarter 2008 Financial Results 3Health News:Medifast Announces First Quarter 2008 Financial Results 4Health News:Medifast Announces First Quarter 2008 Financial Results 5Health News:Medifast Announces First Quarter 2008 Financial Results 6Health News:Medifast Announces First Quarter 2008 Financial Results 7Health News:Medifast Announces First Quarter 2008 Financial Results 8
...pecies with unpaired electrons have been implicate...ancer. The scientific community has been trying ha... free radicals by supplementation with anti-oxidan...radicals. // Anti-oxidants are abundant in fruits ...
... been a quest regarding the treatment of AIDS/HIV ...e the initiation of a global research, AIDS still ...imately five percent of patients with HIV, or huma...op AIDS, or do so very slowly.// Past research su...
...h team led by Professor Claudio Soto from the Univ...rion’ proteins behind such diseases in the blood o... the proteins that cause Mad Cow disease, raising ... form of the condition, Creutzfeldt-Jackobson dise...
... are often the ones who make fewer visits to the d...appens in spite of the fact that smoking puts them...s.// The finding holds true regardless of age, ge...cioeconomic status, location and insurance coverag...
Other Medicine News:Health News:Study holds promise for new way to fight HIV 2Health News:Blood Test To Detect Creutzfeldt-Jakob Disease/Mad Cow Disease 2
(Date:5/9/2008)...sts Cytopia,s development of early pipeline cancer...Newswire-FirstCall/ -- Cytopia Limited,(ASX: CYT) ...ancer drug,discovery and development collaboration...ent leverages Cytopia,s early stage drug discovery...d therapeutics that is one of the,fastest growing ...
(Date:5/8/2008)...ion,s Largest Renal Research Network Completes 13 ...ve Trials in Late Stage Development, EL SEGUNDO, ...arch(R),(DCR), a Phase I-IV clinical trial researc...rug and device research and development for FDA ap...rials in 2007 and has another 34,active trials in ...
(Date:5/8/2008)...AMI, May 8 /- Globus Medical, Inc., t...rer in the world and a recognized,leader in motion...letion of,enrollment in its SECURE(R)-C Cervical A...s designed to mimic the normal motion of the spine...s an alternative to fusion in,the treatment of sym...
(Date:5/8/2008)...NSE demonstrated significant improvement in ADHD s...FirstCall/ -- Shire plc (LSE: SHP,Nasdaq: SHPGY),...oday,presented the results of a phase III pivotal ...provements in Attention Deficit Hyperactivity,Diso...and efficacy,endpoints., "Adults with ADHD often ...
Breaking Medicine Technology:Cytopia Announces Novel Anti-Cancer Drug Development Collaboration 2Cytopia Announces Novel Anti-Cancer Drug Development Collaboration 3DaVita Clinical Research Completes Record Number of Renal Trials in 2007 2Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 2Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 3Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 4Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 5The Northern Illinois University Murders Due to Chemical Imbalances or Chemical Balancers Drugs 3F Fred A Baughman Jr MD Neurologist Child Neu 12440 1The Northern Illinois University Murders Due to Chemical Imbalances or Chemical Balancers Drugs 3F Fred A Baughman Jr MD Neurologist Child Neu 12440 2The Northern Illinois University Murders Due to Chemical Imbalances or Chemical Balancers Drugs 3F Fred A Baughman Jr MD Neurologist Child Neu 12440 3AstraZeneca Response to February 21 2008 Ruling In Re 3A Alabama Medicaid Pharmaceutical AWP Litigation cv2005 219 Circuit Court of Montgomery A 3453 1Keryx Biopharmaceuticals Inc to Hold Conference Call on Fourth Quarter and Year End 2007 Financial Results on Monday February 25 at 8 3A30 A M ES 3449 1Keryx Biopharmaceuticals Inc to Hold Conference Call on Fourth Quarter and Year End 2007 Financial Results on Monday February 25 at 8 3A30 A M ES 3449 2FDA Grants Priority Review for Daiichi Sankyo Lilly Drug prasugrel 1407 1FDA Grants Priority Review for Daiichi Sankyo Lilly Drug prasugrel 1407 2FDA Grants Priority Review for Daiichi Sankyo Lilly Drug prasugrel 1407 3
...sed Tumor Blood Vessel,Density and Serum PSA Level...lif., April 17, 2007,/PRNewswire-FirstCall/ -- Per...opharmaceutical company developing targeted,monocl...patitis C,virus (HCV) infection, today announced t...nnual Meeting of the American,Association for Canc...
...Call/ - Oncolytics,Biotech Inc. ("Oncolytics") ann... of , New York, entitled "In Vivo Synergy between,...Human HCT116,Xenografts" is scheduled to be presen...esearch (AACR) Annual Meeting in Los,Angeles, CA. ...earchers found that treatment of human colon cance...
Other Medicine Technology:Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 2Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 3Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 5Oncolytics Biotech Inc. Research Collaborators Demonstrate,Reovirus/Gemcitabine Combination Has Synergistic Effect Against,Human Colon Cancer Cell Lines 2Oncolytics Biotech Inc. Research Collaborators Demonstrate,Reovirus/Gemcitabine Combination Has Synergistic Effect Against,Human Colon Cancer Cell Lines 3
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem.
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem.
Micro Seal Acetabular Liner
Longevity Crosslinked Polyethylene Liners
Medicine Products: